Pacific Biosciences Of California (PACB) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 17.54% |
| 10 | Pacific Biosciences Of California | 394.53 Mn | 157.66 Mn | 12.64 Mn | 13.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.79% |
| Mar 31, 2026 | 54.53% |
| Dec 31, 2025 | 21.79% |
| Sep 30, 2025 | 20.97% |
| Jun 30, 2025 | 16.26% |
| Mar 31, 2025 | -73.56% |
| Dec 31, 2024 | 26.71% |
| Jun 30, 2024 | -25.26% |
| Mar 31, 2024 | -27.14% |
| Dec 31, 2023 | -45.72% |
| Sep 30, 2023 | -41.29% |
| Jun 30, 2023 | 4.89% |
| Mar 31, 2023 | -37.80% |
| Dec 31, 2022 | -63.20% |
| Sep 30, 2022 | -38.81% |
| Jun 30, 2022 | -41.83% |
| Mar 31, 2022 | -36.66% |
| Dec 31, 2021 | -30.42% |
| Jun 30, 2021 | -44.49% |
| Mar 31, 2021 | 15.56% |